Dr. Jackson has over 20 years of experience leading research teams for large pharmaceutical companies and biotechnology companies including Pfizer, Novartis, MedImmune, Agensys/Astellas and Ambrx. Dr. Jackson has led teams developing small molecule inhibitors, antibody drug conjugates, bispecific antibodies and bispecific T-cell engagers to treat cancer patients.
Dr. Jackson is currently the Director of Biology at TB Alliance, a non-profit company focused on developing novel drug regimens to shorten the treatment time for TB patients.
Dr. Jackson has either led or played a critical role in the submission of several INDs and served as the biology expert on clinical teams. He has published in high impact peer-reviewed journals, including Science, authored book chapters and serves as an ad-hoc reviewer for several journals.
Dr. Jackson has a doctorate from Northwestern University where he studied Biophysics and Molecular Biology in the Department of Biochemistry, Molecular Biology and Cell Biology. He has a Masters degree in Molecular Biology from California State University Dominguez Hills (CSUDH) and a Bachelors degree in Biology from the University of California Los Angeles (UCLA).